Quince Therapeutics
QNCX
63 hedge funds and large institutions have $523M invested in Quince Therapeutics in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
26% more funds holding
Funds holding: 50 → 63 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0.2% → 0.19% (-0%)
12% less capital invested
Capital invested by funds: $594M → $523M (-$71.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.2M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$8.44M |
| 3 |
PHAM
Pacific Heights Asset Management
San Francisco,
California
|
+$5.68M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$4.87M |
| 5 |
BlackRock
New York
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.86M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.26M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.26M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$681K |
| 5 |
Goldman Sachs
New York
|
-$443K |
QNCX Hedge Fund Activity: Q1 2020 in Review
63 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2020, worth a combined $523M — down 12% from $594M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new QNCX positions and 2 closed out — a net gain of 13 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.2M. The largest seller was Morgan Stanley, cutting an estimated $3.86M.
- 63 institutional investors held Quince Therapeutics (QNCX) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $523M of Quince Therapeutics stock for Q1 2020, down 12% quarter-over-quarter.
- 15 funds opened new Quince Therapeutics positions in Q1 2020 and 2 closed out, a net change of +13 holders.
- The largest Quince Therapeutics buyer in Q1 2020 was Citadel Advisors, an estimated $12.2M added.
- The largest Quince Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $3.86M sold.
Based on aggregated 13F filings for Q1 2020.